RxDoctor Payments DataLook up a doctor →

Andrew Lerman, MD

Epilepsy · Miami, FLNPI 1407173974

Payments from drug & device makers

$4,465,313in general payments, 2019–2025

Across 1,636 payments — averaging $2729.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eli Lilly$3.3M
  • UCB SA$345K
  • Novartis$313K
  • Argenx US, Inc.$121K
  • Neurocrine Biosciences, Inc.$104K
  • Takeda Pharmaceuticals U.S.A., Inc.$73K
  • plus $168K from 54 others
$155,915in research payments, 2019–2025

Across 8 payments — averaging $19,489 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$156K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Eli Lilly36$3,342,484
UCB SA2$345,260
Novartis21$312,582
Argenx US, Inc.58$120,647
Neurocrine Biosciences, Inc.200$103,686
Takeda Pharmaceuticals U.S.A., Inc.40$72,716
Amneal Pharmaceuticals LLC91$33,584
Amgen16$29,075
Genentech, Inc.3$23,230
Neurelis, Inc.63$22,724
AbbVie(2 entities)207$16,070
MDD US Operations, LLC34$9,616
UCB, Inc.124$9,349
Eisai Inc.9$4,448
Scilex Pharmaceuticals Inc.28$4,236
Abbott23$2,302
Upsher-smith Laboratories LLC71$1,251
Jazz Pharmaceuticals Inc.38$947
SK Life Science, Inc.40$837
Pfizer45$837
Biohaven Pharmaceuticals, Inc.49$693
Teva Pharmaceuticals USA, Inc.34$691
Greenwich Biosciences, Inc.26$596
Lilly USA, LLC26$595
Acorda Therapeutics, Inc29$560
Biogen28$472
Adamas Pharmaceuticals, Inc.30$435
Sunovion Pharmaceuticals Inc.30$395
Lundbeck LLC14$348
AstraZeneca(2 entities)16$342
Biohaven Pharmaceutical Holding Company Ltd.19$324
Kyowa Kirin, Inc.16$309
Supernus Pharmaceuticals, Inc.22$294
Livanova USA, Inc.9$219
TG Therapeutics, Inc.5$209
Impel Pharmaceuticals Inc.10$189
Bristol Myers Squibb9$184
Avion Pharmaceuticals11$168
Acadia Pharmaceuticals Inc8$162
Sanofi7$152
Merz Pharmaceuticals, LLC7$140
CSL Behring6$128
Johnson & Johnson(2 entities)5$126
Octapharma USA, Inc.6$126
Axsome Therapeutics, Inc.4$109
Sumitomo Pharma America, Inc.4$106
Mallinckrodt Hospital Products Inc.3$100
Boston Scientific4$91
Alfasigma USA, Inc.4$89
Harmony Biosciences LLC2$89
F. Hoffmann-la Roche AG1$80
GE HealthCare2$78
Aquestive Therapeutics, Inc.5$77
Otsuka America Pharmaceutical, Inc.3$70
GRT US Holding, Inc.3$65
Banner Life Sciences, LLC3$64
Tanabe Pharma America, Inc.3$62
Avanir Pharmaceuticals, Inc.3$56
Alnylam Pharmaceuticals Inc.2$52
Averitas Pharma Inc.2$51

How this compares

$4,465,313 in reported general payments places this provider in the 95th percentile of 23 epilepsy providers in Florida.

See all epilepsy providers in Florida →

Medicare billing

Part B allowed, 2024
$641,608
Medicare patients
535
Services billed
41,075

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other epilepsy in Miami

See the full list for Florida →

Where these figures come from

Is this you, or does something look wrong? →